Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, I may be naive, but I just got filled shorting Feb 7.5 puts at $0.75. Didn't expect it to be that easy. There is some serious negativity out there on this stock now. I guess that's why I made this trade.
Chris
I don't know if any of you have ever noticed who Yahoo lists as one of the major holders of COR. Anyone ever heard of Renaissance Technologies?
They are in the same biz as my company, but way more famous. However, I don't think we can conclude anything specifically by their COR holdings. They have a lot to spread around.
Chris
gfp, I think I'm the one from whom you paraphrased a response regarding the possible explanation for so many 100 share orders. I'm afraid you misinterpreted what I said since I didn't mean to imply that there was any relationship between lots of 100 share orders and buying or selling.
First of all, most institutional investors (funds, whatever) pay per share and not per ticket. When we're trying to add to or take away from a position, our first concern is not moving the market unduly but still getting our order filled as quickly as possible. Therefore, we'll use our prime brokerage supplied trading software to break our entire order up into little pieces and feed them to the market according to some parameters. In some equities this means lots of 100 share child orders, in others up to 1000 or 5000 shares. Since we're paying per share, we don't care how many transactions it takes.
That's the best explanation I can give as to why you see lots of little orders in any equity. Also know that this explanation is simplified, since more detail would probably lead to more questions I don't want to answer :)
Regards,
Chris
Kelly's Heroes - wow, brings back memories. Hippies, gold, guns, and Clint. I loved that movie as a kid.
Good luck to you, Harry, and all those folks in the line of the fire.
Chris
Aiming: I almost agree with 1), however my perception at this point is that DNP actually punted instead of blessed. As far as 2), I have no knowledge that COR has appropriately and fully tested the remaining pre-clinical ampakines. And given COR's history, why would anyone assume so?
I've refrained from posting much here as the teeth gnashing is rampant already. Now that I've already responded about something else, I'll just say that I'm disappointed in COR management and myself. I'm not a neuro/bio tech CEO. I haven't had many discussions with the FDA over the last year or more about my company's research area. But if I was and I had, I darned well would have felt this train wreck coming and explained to my shareholders how/why we were going to avoid it. Heck, if we're honest with ourselves, the signs were there to be read. If we (small investors) were being tickled by these signs, COR management should have been feeling the dagger point in the ribs.
I'm mad at myself for "trust" creeping into my investments. Never again. Well, I've said that before :O In the interest of disclosure, I'm going to pick an opportune moment based on my best judgment to exit my COR position, in the near future. Money is dead here for a time or forever. Either way, better opportunities exist. It was fun following your discussions for the last year.
Regards,
Chris
OT - Robert Jordan died today. Any Wheel of Time fans here?
Yes. I also want to take back all my swearing at him for taking so long between books. Never knew he had a serious medical condition.
Since then I've found George R. R. Martin but he writes more slowly than Jordan did.
You're right. There's no way a deal is imminent. They wouldn't have taken money now if there was any chance of an equity investment as part of a deal this year. If that is not the case and a deal is announced within a couple of months, I'll be even more irate than I am right now.
We'll see about 2008.
I'm not a hand wringer, but I'll throw out my real worry here.
inlicensing....
Only thing I can see that justifies a financing here. Stoll saw something he had to have. Hope I'm wrong though. Otherwise, I just don't get it. It's not like this is the greatest time (in the credit markets) to do a financing deal.
Chris
Wow. It was crazy the first few seconds of the open.
2.50
2.45
2.42
2.20
2.16
2.12
2.35
2.19
2.25
2.35
Not all the trades but gives an impression of someone wanting out.
Chris
Strange pre-market IMO. Bloomberg is showing 55k shares traded already. Anybody heard anything? Can't find anything on the wires either.
Chris
On my Redi T&S, NLS corresponds to NASD and NDD corresponds to NAQS. NAQS = Nasdaq stock exchange. From my contact at GS, NASD (while you might think this is Nasdaq) is now the code used to signify the alternative display facility network (ADFN). Some ECNs will use ADFN (now NASD) to post quotes. Direct Edge and TracData are two examples.
That's all I know.
Chris
John, I have one explanation, even though it might not be the right one. At the fund I work for, we use smart trading algorithms accessible through GS Redi platform. When we add or remove positions, we usually feed a large pile of stock through these algorithms to get decent executions without moving the market. This technique results in mostly 100-200 share lots firing off over the course of the time window we specify.
I prefer to take an occasional large position where I have confidence that I won’t get killed and then wait for the story to unfold. With this approach, you don’t need a lot of successes to be successful because you don’t run up huge losses.
Dew, you've just distilled my approach and it took me a long time to figure it out. But one day I realized that I wasn't a bad biotech picker, I was just a mediocre seller. I think that I've had an opportunity to sell every biotech equity (that's all I trade) at some point for a very nice gain. At this point in my life I'm content to wait for that gain to occur and then be a disciplined seller. It works.
Chris
Cortex and the University of Alberta Complete Patent License Agreement
Thursday May 10, 8:30 am ET
-- Rights Could Broaden the Use of AMPAKINE(R) Compounds to prevent Opiate- and Barbiturate-Induced Respiratory Depression --
http://biz.yahoo.com/bw/070510/20070510005193.html?.v=1
Sorry for the double post :o
OT: rgreg12 & Mg - I would switch to magnesium citrate, aspartate or malate. Anything but oxide.
OT: rgreg12 & Mg - I would switch to magnesium citrate, aspartate or malate. Anything but oxide.
May issue of Wired magazine has a one-pager on drugs being made using plants and animals. Companies (and drugs) mentioned:
GTC Bio (animal) - Atryn
Planet Biotechnology (plant) - Carorx
Biolex Therapeutics (plant) - Locteron
Ventria Bioscience (plant) - Lactoferrin (not a drug but what was mentioned)
Meristem Therapeutics (plant) - Gastric lipase
Pharming (animal) - Lactoferrin & Rhucin
SemBioSys (plant) - Insulin
Just FYI.
I guess my hope regarding the inlicensing option is that COR has knowledge of a type of compound that would be fantastically synergistic with an ampakine down the road. Meaning that the compound would be brought along through trials alone, but could eventually be paired with an ampakine later for possibly expanded use.
I realize that my hope may be totally naive, but I believe anything else is more a distraction rather than an enhancement of value.
With ARTE, just know that it is on the Reg SHO Threshold Securities list right now. With the new SEC proposal regarding market makers and this list, there may be funds that try to ride some of these names on the long side to create whatever kind of snowball effect upward that they can.
I would give this warning to anyone considering any stock on the SHO list. But to Dew most of all since I appreciate all of the time & info he gives to this board.
Anyone have any comments on Mansbach leaving? Jumping ship or walking the plank?
Blade, I wholeheartedly concur. I wish the barriers, perceived or otherwise, weren't so high so that these plans were more popular.
I agree. He's guessing. Don't think that Stoll could deny to answer point blank in a public forum and then hand that info out, behind the scenes, to someone he knows would disseminate it as well.
I posted a question soon after the conf call, but I assume it was uninformed since no one answered. However, I'll ask again. Does anyone find anything interesting about Stoll stating that he's optimistic in the pre-clinical compounds because they're more powerful than CX-717 and that COR might be able to use a lower dose (I read mass-mg,mcg,etc) to achieve the same effect?
To me that implies that the expected "effect" of the drug isn't the problem (remember same efficacy) but rather what happens to the drug during metabolization and afterwards. Is that not a hepatic concern? Some of you knowledgeable folks please clue me in.
Thanks
Mr. Stoll just answered a question related to two backup compounds that are nearing toxicology studies. He expressed some hope by saying they were more powerful than CX-717 and therefore a lower dose may be needed to achieve the same effect as CX-717.
To me, this means that the toxicology problem (undisclosed) is related to the "amount" (mass) of drug and not related to potency/effect produced. How far off am I when I wonder if he's not indirectly saying that this is a metabolization problem?
Please remember this question is asked in total ignorance. :o
I believe that I read that in the Times. Now, if I could only remember the name. Something to do with Mt. Sinai School of Medicine I think.
MYGN: What do you folks think?
Tuesday November 15, 7:15 am ET
Flurizan Reverses Disease Course and Improves Cognitive Function in Follow-on
SALT LAKE CITY, Nov. 15 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - News; www.myriad.com) announced today that an analysis of data from its Phase 2 follow-on study of Flurizan(TM) in patients with mild Alzheimer's disease showed that study participants improved as a group, regaining cognitive ability from months 12 through 18. Results of the 6-month follow-on study were presented today at the Neuroscience 2005 meeting in Washington, D.C., by Sandra E. Black, M.D., Professor of Neurology at the University of Toronto and lead investigator in Canada for the Phase 2 trial of Flurizan in patients with Alzheimer's disease.
The Phase 2 trial of Flurizan monitored patients with Alzheimer's disease for a period of 12 months. At the end of the 12-month period, the group of mild patients taking 800 mg twice daily showed an average decline from their baseline score at enrollment of 2.64 points on the Alzheimer's Disease Assessment Scale -- Cognitive Function Subscale (ADAS-cog). In contrast, the placebo group experienced a 3.78 point decline over the same 12 months. In the follow-on to the Phase 2, patients on Flurizan for three additional months regained 0.38 points to 2.27, an improvement of 14 percent, and by 18 months the average ADAS-cog score had further improved to 1.78 points, a total gain in cognition of 0.86 points. These data demonstrate an increase in cognition upon continued treatment that amounted to a 33% improvement over the follow-on period.
"The 18-month follow-on data are striking in that Flurizan-treated patients appear to be regaining cognitive functions like memory and thinking ability that they had previously lost to the disease," said Daniel Christensen, M.D., Clinical Professor of Neurology, Psychiatry and Pharmacology at the University of Utah. "This is a truly exciting finding in the development of a potential future treatment of Alzheimer's disease."
During months zero to 12, mild patients in the 800 mg BID dose group declined by a total of 1.27 points on the test that is considered a global measure of Alzheimer's disease, Clinical Dementia Rating -- Sum of Boxes (CDR-sb), for an average decline of 0.11 points per month. This compares with patients on placebo who declined 2.09 points during this 12-month period, or 0.17 points per month. Over the six-month follow-on period, patients declined 0.05 point per month, or 0.29 points in total. These data indicated an improvement in the rate of decline during the follow-on period to less than half the rate of decline in months 0 to 12. These same patients declined in the follow-on at a rate that was less than one third of the rate seen in the placebo group during the first 12 months.
Tested with the functional measure of Alzheimer's disease, ADCS-ADL (Alzheimer's Disease Cooperative Study -- Activities of Daily Living), mild patients in the 800 mg BID group demonstrated a 5.4 point decline over 12 months, for a rate of 0.45 points per month. The placebo group declined 8.09 points during the same period, for a rate of 0.67 points per month. During months 12 through 18, the rate of decline in ADCS-ADL among patients on 800 mg twice-daily Flurizan continued at 0.47 points per month, a similarly reduced rate as seen in the first 12 months.
"The follow-on data are very encouraging to our clinical development program with Flurizan in mild Alzheimer's disease," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "This result is consistent with the compound's mechanism of action. We look forward to completing enrollment in the Phase 3 trial in order to confirm the efficacy of Flurizan in a larger patient population."
IPIX is definitely setting up another decent bullish triangle formation here.